PREVENTION OF ERYSIPELAS IN THE EARLY POSTOPERATIVE PERIOD AFTER THE IMPOSITION MIKROLIMFOVEIN ANASTOMOSIS IN PATIENTS AFTER BREAST CANCER LYMPHEDEMA
https://doi.org/10.20538/1682-0363-2013-6-129-133
Abstract
The aim of work is valuation of the effectiveness of autologous lymphocytes activated by complex of cytokines to prevent erysipelas of patients with after breast cancer syndrome.
The estimate of influence of activated autologous lymphocytes to erysipelas. The treatment results of 128 patients with secondary lymphedema of the upper limb II–III stage after curative treatment of breast cancer are included in the work.
Activated roncoleukin auto lymphocytes injections were performed in the forearm of the affected limb to the main group’s patients.
17.4% faces relapses were recorded in the comparison group. while the group with the usage of activated roncoleukin autologous lymphocytes had achieved significant reductions in recurrent of erysipelas up to 5%.
About the Authors
M. A. Smagin
Institute of Clinical and Experimental Lymphology SB RAMS, Novosibirsk
Russian Federation
Smagin Mikhail A.
Russian Federation
Smagin Mikhail A.
M. S. Lubarsky
Institute of Clinical and Experimental Lymphology SB RAMS, Novosibirsk
Russian Federation
Lubarsky Mikhail S.
Russian Federation
Lubarsky Mikhail S.
O. A. Shumkov
Institute of Clinical and Experimental Lymphology SB RAMS, Novosibirsk
Russian Federation
Shumkov Oleg A.
Russian Federation
Shumkov Oleg A.
V. V. Nimaev
Institute of Clinical and Experimental Lymphology SB RAMS, Novosibirsk
Russian Federation
Nimaev Vadim V.
Russian Federation
Nimaev Vadim V.
O. V. Poveshenko
Institute of Clinical and Experimental Lymphology SB RAMS, Novosibirsk
Russian Federation
Poveshenko Olga V.
Russian Federation
Poveshenko Olga V.
References
1. Kosenkov A.I., Narenkov V.M., Abramov Yu.A. Erysipelas as a cause of lymphedema. Surgery, 2005, no. 11, pp. 51–53 (in Russian).
2. Damstra R.J. Erysipelas as a sign of subclinical primary lymphoedema: a prospective quantitative scintigraphic study of 40 patients with unilateral erysipelas of the leg. Br. J. Dermatol., 2008, vol. 158 (6), pp. 1210–1215.
3. Perelló-Alzamora M.R. et al. Clinical and epidemiological characteristics of adult patients hospitalized for erysipelas and cellulitis. Eur. J. Clin. Microbiol. Infect. Dis., 2012, Feb 3 (Epub ahead of print).
4. Zvonik M., Földi E., Felmerer G. The effects of reduction operation with genital lymphedema on the frequency of erysipelas and the quality of life. Lymphology, 2011, Sep. 44 (3), pp. 121–130.
5. Vignes S., Dupuy A. Recurrence of lymphoedemaassociated cellulitis (erysipelas) under prophylactic antibiotherapy: a retrospective cohort study. J. Eur. Acad. Dermatol. Venereol., 2006, vol. 20, no. 7, pp. 818–822.
6. Pavlotsky F., Amrani S., Trau H. Recurrent erysipelas: risk factors. J. Dtsch. Dermatol. Ges., 2004, vol. 2, no. 2, pp. 89– 95.
7. Pereira de Godoy J.M., Azoubel L.M.O., de Fоtima Guerreiro Godoy M. Erysipelas and lymphangitis in patients undergoing lymphedema treatment after breast-cancer therapy. Acta. Dermatoven APA, 2009, vol. 18, no. 2, pp. 63–65.
8. Cireap N., Nariţa D., Ilina R., Nicola T. Еrysipelas of upper limb: a complication of breast cancer surgery. Jurnalul de Chirurgie, 2010, vol. 6, no. 2, pp. 132–136.
9. Leclerc S. et al. Recurrent erysipelas: 47 cases. Dermatology, 2007, vol. 214 (1), pp. 52–57.
10. Gunderson C.G., Martinello R.A. A systematic review of bacteremias in cellulitis and erysipelas. J. Infect., 2012, Feb., 64 (2), pp. 148–155.
11. Bubnova N.A., Egorova V.N. Lessons learned Roncoleukin (recombinant interleukin-2) in the treatment of surgical diseases: manual for physicians. St. Petersburg, Аlter Ego Publ., 2010. 80 p. (in Russian).
12. Egorova V.N., Popovich A.M. Roncoleukin®. Comprehensive treatment of infectious diseases. St. Petersburg, Alternative Printing, 2004. 48 p. (in Russian).
13. Babachenko I. et al. "Old" and "new" disease in children in modern conditions: scientific and practical materials. Conf. St. Petersburg, 2011. Pp. 48–60 (in Russian).
14. Razuvanova I.A. Key issues of infection control: proceedings of the Russian scientific-practical. Conf. St. Petersburg, BMA Publ., 2004. P. 200 (in Russian).
15. Degtyareva M.V. Efficacy of human recombinant interleukin-2 (Ronkoleukin®) in treatment of severe neonatal bacterial infections complicated with lymphopenia. Abstracts of XXII European Congress of Perinatal MMedicine. Granada, Spain, 2010. Vol. 23, Supl. 1. P. 639–640.
Review
For citations:
Smagin M.A., Lubarsky M.S., Shumkov O.A., Nimaev V.V., Poveshenko O.V. PREVENTION OF ERYSIPELAS IN THE EARLY POSTOPERATIVE PERIOD AFTER THE IMPOSITION MIKROLIMFOVEIN ANASTOMOSIS IN PATIENTS AFTER BREAST CANCER LYMPHEDEMA. Bulletin of Siberian Medicine. 2013;12(6):129-133. (In Russ.) https://doi.org/10.20538/1682-0363-2013-6-129-133
Views:
2338
Email this article 